Patient Centricity

Patients always at heart.

A recent report released by The Economist Intelligence Unit (EIU)1 and commissioned by us confirmed what we’ve known for years – that drugs developed with patients at heart are more likely to launch.

Throughout our years helping discoveries come to market, one thing has remained constant – the more patient-focused the process, the better. That’s why all our services take patient input to heart before, during and after a clinical study.

Bar graph illustrating the increase in likelihood of launch in patient-centric clinical trials.

Source: The Innovation Imperative: The Future of Drug Development, The Economist Intelligence Unit, 2018.

 

Patient-centricity at every point

Pre-Study:
  • We design protocols to identify and address potential practical barriers to study participation
  • We use a combination of web listening, patient, caregiver, and site staff input to get a clear picture of the patient burdens to best care for volunteers through recruitment and retention
  • We proactively seek opportunities to address the needs of commercial stakeholders and build a better value story
  • Our regulatory experts incorporate guidance to address agency requirements from a patient-centric perspective
During Study:
  • To make the process as easy as possible for patients, we can help with eConsent, home nursing, direct-to-patient drug shipments, patient apps, and video dosing
  • Our Patient Sensor Solution allows for continuous data collection with wearables to remotely capture, transmit, and store data in a secure platform
Market Access and Beyond
  • We can help patients understand study outcomes and ways to transition to a post-study treatment plan
  • To get needed therapies to market as quickly as possible, we identify and develop ways to speed up market access
  • Through our Managed Access Programs we facilitate early access to promising new medicines for patients with unmet needs  Table describing how Parexel's Patient Innovation Center transforms clinical development and commercialization with engaged patients.


 

We are always available for a conversation.

*